Kazia Therapeutics (NASDAQ:KZIA) Stock, Quote.Headers.trade-ideas

Kazia Therapeutics

Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing innovative anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors.

Image49

News

Intraday Update

Markets

Movers

Trading Ideas

AEON

AGRI

AMIX

AREB

ASLN

ASTL

COIN

DATS

EAST

FSLR

FUFU

HUMA

INOD

KZIA

LCFY

LCID

LXEO

MIRA

MLEC

MSTR

NAAS

NOVA

PETZ

POWW

Qualigen Therapeutics, Inc. - Common Stock

QLGN

SCNI

SEDG

SQNS

TSLA

UPST

VTAK

Why SolarEdge Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Monday&#39;s Mid-Day Session

Citibank

Earnings

Eurozone

Commodities

NISN

SISI

ZAPP

S&amp;P 500 Rises Over 1%; Citigroup Reports Upbeat Q2 Results

ACHR

ASPI

BDRX

BILI

CGBS

COCO

ERIC

EVGO

EYPT

FWRD

HOVR

IMMP

LIPO

PEGY

RNLX

SANW

SNTG

SXTC

TOYO

VALU

VRPX

VSTM

YGMZ

Why ASP Isotopes Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Friday&#39;s Mid-Day Session

Kazia Therapeutics Limited - American Depositary Shares

Kazia Therapeutics Ltd

Microsoft Corporation&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) vice chair and president, Brad Smith, has raised concerns about potential foreign interference in the upcoming <a href="https://www.benzinga.com/topic/2024-presidential-election">2024 U.S. presidential election</a>.
What Happened: On Wednesday, during his opening testimony at a Senate Intelligence Committee hearing on <a href="https://www.benzinga.com/general/politics/24/09/40743037/putin-says-russia-backs-harris-and-her-infectious-laugh-for-2024-election-we-will-root-for-her">foreign election interference</a>, Smith warned of &#8220;real and serious&#8221; threats, <a href="https://thehill.com/policy/technology/4887227-microsoft-election-iran-trump-russia-harris/">reported</a> The Hill.
He pointed out that the election has become a battleground for foreign actors, specifically Iran and Russia, against presidential candidates Donald Trump and Kamala Harris respectively.
&#8220;We know that there is a presidential race between Donald Trump and Kamala Harris, but this has also become an election of Iran vs Trump and Russia vs Harris,&#8221; he stated.
See Also: <a href="https://www.benzinga.com/news/24/09/40893054/mark-cuban-says-he-would-buy-rupert-murdochs-fox-news-and-elon-musks-x-but-there-are-some-obstacles?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Mark Cuban Says He Would Buy Rupert Murdoch&#8217;s Fox News And Elon Musk&#8217;s X But There Are Some Obstacles: &#8216;If I Had Enough… I&#8217;d Buy It In A Heartbeat&#8217;</a>
Smith also shed light on the <a href="https://www.benzinga.com/news/24/09/40760931/trump-vs-harris-who-do-russia-iran-and-china-favor-in-2024-election-intelligence-officials-weigh-in">combined efforts of Russia, Iran, and China</a> in undermining democracy. He cited a recent Microsoft report that revealed Russian influence operations behind a false <a href="https://www.benzinga.com/news/24/09/40915084/kremlin-aligned-group-behind-false-hit-and-run-allegations-against-kamala-harris-microsoft-says">viral video accusing Harris of a hit-and-run</a>.
He stressed the importance of tech companies upholding two principles: preserving the right to free expression and protecting the American electorate from foreign deception.
Smith called on tech companies to put in place safeguards, especially around AI-generated content, and to educate candidates about AI risks.
Subscribe to the <a href="https://bztechtrends.beehiiv.com/subscribe" target="_blank" rel="noreferrer noopener">Benzinga Tech Trends newsletter</a> to get all the latest tech developments delivered to your inbox.
Why It Matters: Smith&#8217;s testimony comes at a time when concerns over foreign interference in the election through online disinformation and misinformation campaigns are escalating.
He testified alongside Nick Clegg, the president of global affairs at Meta Platforms, and Kent Walker, the president and chief legal officer for Google's Alphabet, the report noted.
On Tuesday, in a blog post, Microsoft revealed that its Threat Analysis Center noticed a <a href="https://www.benzinga.com/news/24/09/40912191/harris-walz-campaign-targeted-by-russian-hackers-microsoft-threat-analysis-center-notices-shift-in-t">shift in tactics by Russian hackers</a> who targeted the campaign of Democratic nominee Harris.
Earlier this month, the Justice Department seized over 30 web domains used by Russia for covert campaigns. The FBI also revealed that Iran was behind a hacking of the Trump campaign.
On Wednesday, the FBI said, &#8220;Iranian malicious cyber actors in late June and early July sent unsolicited emails to individuals then associated with President Biden's campaign that contained an excerpt taken from stolen, non-public material from former President Trump's campaign as text in the emails.&#8221;
Check out more of Benzinga&#8217;s Consumer Tech coverage by <a href="https://www.benzinga.com/topic/consumer-tech" target="_blank" rel="noreferrer noopener">following this link</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40914747/jpmorgan-ceo-jamie-dimon-thinks-social-media-platforms-like-tiktok-and-facebook-are-a-total-stupid-w?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">JPMorgan CEO Jamie Dimon Thinks Social Media Platforms Like TikTok And Facebook Are &#8216;A Total Stupid Waste Of Time&#8217;</a></li>
</ul>
Disclaimer: This content was partially produced with the help of <a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a> and was reviewed and published by Benzinga editors.

MSFT

'This Has Also Become An Election Of Iran Vs Trump And Russia Vs Harris' — Microsoft President Brad Smith Warns About Foreign Interference In 2024 Election

In the run-up to the presidential election, Donald Trump, the Republican nominee, has voiced his disapproval of the Federal Reserve&#8217;s recent decision to <a href="https://www.benzinga.com/economics/macro-economic-events/24/09/40926026/federal-reserve-delivers-bold-0-5-rate-cut-signals-further-easing-ahead">slash its benchmark interest rate by half a percentage point</a>. Trump suggests this move could be indicative of a faltering U.S. economy or a politically motivated action.
What Happened: Trump expressed skepticism over the Federal Reserve&#8217;s decision. This critique comes as the November presidential election is just around the corner, <a href="https://www.ft.com/content/da9347a5-b4db-4987-94c9-2aeb20624726">reported</a> The Financial Times.
&#8220;I guess it shows the economy is very bad to cut it by that much, assuming that they are not just playing politics,&#8221; said Trump.
Trump has previously voiced his displeasure with Federal chair Jerome Powell, accusing the independent central bank of political bias. In a conversation with Bloomberg News, Trump cautioned Powell against reducing interest rates before the election. However, he also mentioned that he would allow Powell to complete his term as chair if he was &#8220;doing the right thing.&#8221;
In a separate discussion with Fox Business Network, Trump hinted at his intention to replace Powell, blaming him for being &#8220;political&#8221; and predicting he would lower interest rates to &#8220;help the Democrats,&#8221; according to the report.
Trump&#8217;s remarks were made just hours before a campaign rally in the suburbs of New York City on Long Island. His Democratic rival, vice-president Kamala Harris, also reportedly shared her thoughts on the Fed&#8217;s decision, stating the cut would be &#8220;welcome news for Americans who have borne the brunt of high prices&#8221;.
See Also: <a href="https://www.benzinga.com/news/24/09/40890590/chuck-schumer-says-if-government-shutdown-happens-it-will-because-of-republican-poison-pills-the-ame?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Chuck Schumer Says If Government Shutdown Happens It Will Be Because Of &#8216;Republican Poison Pills&#8217; — &#8216;The American People Are Going To Hold Them Responsible&#8217;</a>
Why It Matters: The Federal Reserve&#8217;s decision to cut interest rates by 50 basis points marks the first rate cut in over four years, breaking a streak of 12 consecutive months with rates held steady. This decision came as a surprise to Wall Street analysts who had largely anticipated a more modest 25-basis-point cut.
Earlier this month, Trump had <a href="https://www.benzinga.com/general/politics/24/09/40861372/trump-says-no-federal-rates-cuts-before-2024-election-republican-congress-members-say-the-time-i">expressed his desire</a> for the Federal Reserve to leave rates unchanged ahead of the 2024 presidential election. However, investors and members of Congress were expecting a rate cut.
The anticipation among investors for a 50 basis point interest rate cut was growing, and this expectation could have <a href="https://www.benzinga.com/economics/macro-economic-events/24/09/40919701/investors-betting-on-50-basis-point-rate-cut-expert-says-market-pressure-could-sw">influenced the Federal Reserve&#8217;s decision</a>. The market was pricing in a 63% likelihood of a 50 basis point cut, a significant increase from 34% the previous week.
Image via Shutterstock
Check This Out:
<ul>
<li>Lawmakers Made Huge Investments This Year. <a href="https://www.benzinga.com/gov-trades">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>

Politics

Economics

General

Trump Isn't Happy With Jerome Powell's 50 Bps Rate Cut Maneuver: 'I Guess It Shows The Economy Is Very Bad'

Antivaccine advocate and former independent presidential candidate, Robert F. Kennedy Jr., stated that he might be appointed by former President Donald Trump to select leaders for key public health agencies, should the former president win a second term.
What Happened: Kennedy Jr. disclosed this information during a discussion with conservative commentator Tucker Carlson, as reported by <a href="https://thehill.com/homenews/campaign/4887585-rfk-jr-trump-fda-nih-cdc/">The Hill</a> on Wednesday.
He named the Centers for Disease Control and Prevention, the Food and Drug Administration, and the National Institutes of Health as agencies he might be involved with. Kennedy made this announcement during a Tuesday stop in Wisconsin on Carlson's live tour.
&#8220;President Trump has asked me specifically to do two things. One, to help unravel the capture of the agencies by corrupt influence. In other words, to drain the swamp. And, you know, I had to say something about President Trump,&#8221; said Kennedy Jr.
In a previous conversation with Carlson, Kennedy mentioned that Trump asked him to be part of his transition team if he secures a second term. However, Trump campaign spokesperson Karoline Leavitt labeled discussions about who will serve in a second Trump administration as &#8220;premature&#8221;.
Earlier this month, Democrats and the public health community voiced their concerns over the potential of Kennedy becoming the Health and Human Services secretary in a second Trump term.
See Also: <a href="https://www.benzinga.com/news/24/09/40890069/donald-trump-jr-doesnt-mince-words-democrat-donor-with-a-kamala-harris-bumper-sticker-on-his-car-tri?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Donald Trump Jr. Doesn&#8217;t Mince Words: &#8216;Democrat Donor With A Kamala Harris Bumper Sticker On His Car Tried To Assassinate My Dad&#8217;</a>
Why It Matters: Kennedy&#8217;s potential role in a second Trump administration has been a <a href="https://www.benzinga.com/news/24/07/39898056/robert-kennedy-jr-eyes-role-in-trumps-administration-amid-endorsement-chatter-report">topic of discussion</a> for some time. According to a Benzinga report from July, Kennedy, then an independent presidential candidate, had talks with Trump about endorsing his campaign and possibly taking up a senior role in his administration.
In August, Kennedy <a href="https://www.benzinga.com/general/politics/24/08/40535286/rfk-jr-suspends-2024-presidential-campaign-endorses-trump-to-block-democrats-from-white-house">suspended his presidential campaign</a> and endorsed Trump. He stated that he didn&#8217;t believe he had a real chance of winning the 2024 election and that his continued presence in the race would result in a Democratic Party victory.
Image via Shutterstock
Did You Know? 
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>

Robert Kennedy Jr: Trump Wants Him To Help Pick CDC, FDA, and NIH Leaders — 'Unravel The Capture Of Agencies By Corrupt Influence'

Shaquille O'Neal is widely recognized as one of the greatest basketball players, but since retiring from the NBA, he&#8217;s gained significant <a href="https://www.benzinga.com/markets/24/07/39915962/shaquille-oneal-began-building-his-estimated-500-million-portfolio-by-investing-in-this-tech-titan-w?utm_campaign=partner_feed&amp;utm_source=yahooFinance&amp;utm_medium=partner_feed&amp;utm_content=real_estate">respect for his business expertise</a> and chance encounters.
What Happened: During a 2018 appearance on "The Ellen Show," Shaq shared two pivotal investment stories.
First, he recounted his &#8220;worst investment ever&#8221; — turning down Starbucks.&nbsp;
When Starbucks&#8217; then-CEO Howard Schultz proposed opening locations in African-American communities, Shaq&#8217;s response was skeptical. 
&#8220;Black people don&#8217;t drink coffee,&#8221; he said referring to his earlier thought. This misconception led him to pass on what could have been a lucrative opportunity.
"So now, every time I go to Starbucks, I see black people drinking coffee, I&#8217;m like… [he does a facepalm]."
See Also: <a href="https://www.benzinga.com/general/entertainment/24/09/40824404/shaq-once-said-the-earth-was-flat-and-then-it-cost-him-20m-it-was-like-500k-hate-mail">Shaq Once Said The &#8216;Earth Was Flat&#8217; And Then It Cost Him $20M: &#8216;It Was Like 500K Hate Mail&#8217;</a>
In contrast, Shaq then shared his successful Google investment story.
He recalled a chance encounter at the Four Seasons Hotel in LA around &#8217;93 or &#8217;94, where he was essentially babysitting someone&#8217;s kids during a meeting.
After the meeting, the impressed parent offered him an investment opportunity, saying, &#8220;In the future, you&#8217;re going to be able to type on your phone, search engine, this, do this, boom, boom, boom. You should invest.&#8221;
This turned out to be Google, and Shaq's decision to invest paid off handsomely. Google, now rebranded as Alphabet Inc. has a current market cap of $1.973 trillion, making it the fourth most valuable company in the world.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="Shaq&#039;s Babysitting Gig Led to His Google Riches" width="500" height="281" src="https://www.youtube.com/embed/hKNRieaN0ZI?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Why It&#8217;s Important: This anecdote highlights how unconventional networking can lead to significant investment opportunities in the tech world.
Shaq's Google investment marked the beginning of his successful post-NBA business career, setting him apart from the <a href="https://www.benzinga.com/general/entertainment/23/02/30945804/google-apple-lyft-and-ring-shaquille-oneals-track-record-of-phenomenal-startup-investments">65% of NBA players</a> who reportedly go broke within five years of leaving the game.
Earlier this month, the website CelebrityNetWorth estimated Shaq&#8217;s net wealth to be around $500 million. His investment portfolio includes stakes in various franchises such as Five Guys, Papa John&#8217;s, Krispy Kreme, and his own fast-food chain, Big Chicken.
Apart from Google, other <a href="https://www.benzinga.com/general/sports/24/04/38090549/7-basketball-legends-turn-investment-titans-shaq-lebron-and-more">notable company investments</a> include Ring video doorbell, which was later acquired by Amazon, and Apple.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40911877/jeff-bezos-had-a-habit-of-keeping-an-empty-chair-for-the-most-important-person-in-the-room-at-compan">Jeff Bezos Had A Habit Of Keeping An Empty Chair For The Most Important Person In The Room At Company Meetings: This Strategy Helped The Amazon Founder Build The E-commerce Giant We Know Today</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Tech

Shaquille O'Neal's Estimated $500M Portfolio Includes A Big Bet On Google, But Big Shamrock Made A Critical Error That Makes Him Facepalm Each Time He Steps Into A Starbucks — 'Worst Investment Ever'

BNZIW

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

BNZI

GDHG

Investors now have more ways to invest in or against MicroStrategy Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>), a software company and Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) holder that has outperformed top stocks, asset types and index funds <a href="https://www.benzinga.com/markets/cryptocurrency/24/07/39817792/missed-out-on-nvidia-michael-saylor-says-get-on-the-bitcoin-standard-for-even-better-retur">in recent years.</a>
What Happened: REX Shares and Tuttle Capital Management launched two new ETFs Wednesday to give investors more ways to get exposure <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40878741/canaccord-lowers-microstrategy-price-target-to-173-cites-ongoing-bitcoin-accumulation">to MicroStrategy stock </a>with leveraged and inverse ETFs.
The two companies launched the T-REX 2X Long MSTR Daily Target ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/MSTU#BATS">MSTU</a>) and the T-REX 2X Inverse MSTR Daily Target ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/MSTZ#BATS">MSTZ</a>).
"These are the first ETFs to provide investors with 200% leveraged exposure and -200% inverse exposure to the daily price movement of MicroStrategy (MSTR), allowing traders to capitalize on MSTR's exposure to the Bitcoin market," the companies said.
The launch comes after <a href="https://www.benzinga.com/markets/cryptocurrency/24/08/40399008/mstx-becomes-first-single-stock-leveraged-etf-for-microstrategy-stock-offers-175-exposure">Defiance launched</a> a 1.75X long MicroStrategy ETF and 1.5X Short MicroStrategy ETF in August with the Defiance Daily Target 1.75X Long MSTR ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTX#NASDAQ">MSTX</a>) and Defiance Daily Target 1.5X Short MSTR ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMST#NASDAQ">SMST</a>) respectively.
With the new 2X ETFs, REX and Tuttle have pushed the envelope further.
"The 2X Leveraged and 2X Inverse MSTR ETFs offer traders unparalleled access to MicroStrategy's Bitcoin exposure, whether they're looking to amplify potential gains or hedge against market volatility. We're a product of our ability to redefine what's possible in the ETF industry," Tuttle Capital Management CEO Matthew Tuttle said.
REX Shares CEO Greg King said the new ETFs help provide tools to traders "to engage with a company that's pushing the boundaries in digital assets."
"MicroStrategy's forward-thinking approach presents a compelling opportunity for traders seeking additional ways to trade the stock," King added.
The launches follow several other leveraged and inverse ETFs from REX and Tuttle Capital. The two companies launched the T-REX 2X Long Bitcoin Daily Target ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/BTCL#BATS">BTCL</a>) and T-REX 2X Inverse Bitcoin Daily Target ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/BTCZ#BATS">BTCZ</a>) in July.
Read Also: <a href="https://www.benzinga.com/etfs/specialty-etfs/24/09/40802938/fund-manager-who-bet-against-jim-cramer-and-cathie-wood-has-new-anti-woke-etf-puts-profits-ah">Fund Manager Who Bet Against Jim Cramer And Cathie Wood Has New Anti-Woke ETF: &#8216;Puts Profits Ahead Of Politics, DEI &amp; ESG&#8217;</a>
Why It's Important: MicroStrategy has been a top-performing stock, gaining 94% year-to-date in 2024 and gaining 790% over the last five years.
The company has also seen shares highly volatile as related to the price of Bitcoin because the company is a large holder of the leading cryptocurrency.
MicroStrategy <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40857237/microstrategy-stock-climbs-after-bitcoin-purchase-heres-how-much-btc-michael-saylors-compa">recently announced it bought</a> $1.1 billion worth of Bitcoin bringing its total up to 244,800 Bitcoin. The company <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40919378/microstrategy-raises-875m-in-convertible-notes-plans-further-bitcoin-purchases">recently raised</a> over $800 million to redeem $500 million in senior secured notes and to buy additional Bitcoin.
MicroStrategy began buying Bitcoin in August 2020 and will continue to add more Bitcoin, as co-founder and Executive Chairman Michael Saylor <a href="https://www.benzinga.com/markets/cryptocurrency/22/06/27865236/exclusive-michael-saylors-microstrategy-is-married-to-bitcoin-everything-else-in-the-world">previously told Benzinga.</a>
"We have a simple strategy and our strategy is we just acquire Bitcoin, and we hold the Bitcoin," Saylor told Benzinga.
Saylor said he believes Bitcoin is the best asset in the world.
"Everything else in the world is inferior to Bitcoin. So, if you gave me $1 million and said what do you want to buy, I don't want to buy a sports team, I don't want to buy a building, I don't want to buy a company … all I want to buy is Bitcoin," Saylor previously told Benzinga.
Saylor also previously said that if people hate Bitcoin, they can short MicroStrategy and if they love Bitcoin they could buy the stock.
While investors have more ways to get Bitcoin exposure thanks to cryptocurrency exchanges and Bitcoin ETFs, MicroStrategy remains a popular option to get exposure.
With the new leveraged and inverse ETFs, investors have more ways to predict what will happen to MicroStrategy in terms of the stock going up or down.
Tuttle <a href="https://www.benzinga.com/markets/cryptocurrency/24/01/36500461/exclusive-the-man-who-shorts-cathie-wood-and-jim-cramer-filed-for-new-bitcoin-etfs-why-lev">previously told Benzinga</a> that leveraged and inverse ETFs aren't for all investors, but have an important place in the market.
"They are a tool, just like stocks, bonds, ETFs, mutual funds, options, etc.," Tuttle told Benzinga. "Just like any tool some people will use them correctly and others won't."
Tuttle said that leveraged ETFs can be used by investors as an &#8220;alternative to options.&#8221;
&#8220;Unlike options, they can be traded after hours. They are very conducive to short-term trading strategies.&#8221;
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/top-stories/24/09/40855829/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet">Benzinga&#8217;s &#8216;Stock Whisper&#8217; Index: 5 Stocks Investors Secretly Monitor But Don&#8217;t Talk About Yet</a></li>
</ul>
Photo: Master Tux from Pixabay

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Specialty ETFs

New ETFs

ETFs

$BTC

BTCL

BTCZ

ETF Opportunities Trust T-Rex 2X Long MSTR Daily Target ETF

MSTU

MSTX

ETF Opportunities Trust T-Rex 2X Inverse MSTR Daily Target ETF

MSTZ

SMST

MicroStrategy 2X Leveraged, Inverse ETFs Are Here, Offer 'Unparalleled Access To MicroStrategy's Bitcoin Exposure'

A well-known Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) analyst and iPhone sales forecaster is predicting weak demand of the iPhone 16 with a new hint that expectations <a href="https://www.benzinga.com/news/24/09/40882969/iphone-16-pro-demand-lags-longer-wait-times-globally-china-shows-smaller-gap-analyst">may not be met.</a>
What Happened: Apple <a href="https://www.benzinga.com/news/24/09/40780100/apple-intelligence-ready-iphone-16-with-faster-processor-dedicated-camera-button-announced-check-pri">unveiled the iPhone 16</a> last week and highlighted several new features including its Apple Intelligence generative AI that will be rolled out to consumers.
Early pre-order data shows demand for the iPhone 16 may be lower than expected due to a lack of reasons for existing iPhone owners to upgrade to the latest model.
Apple analyst Ming-Chi Kuo recently said pre-order sales for the iPhone 16 have reached 37 million units.
On Wednesday, Kuo shared another sign that demand could be low.
"Apple employees can already purchase the iPhone 16 with their employee discount. Typically, employees have had to wait several weeks after the release of new iPhone models before being able to buy. This could be another sign that the early demand for the iPhone 16 is below expectations," Kuo <a href="https://x.com/mingchikuo/status/1836445270902808958">tweeted</a>.
Kuo's recent 37 million estimate comes from pre-order data from Apple and supply chain surveys. Average delivery times and shipment volumes could indicate weaker demand for the more expensive iPhone Pro models, Kuo also said.
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent091824">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
 Why It's Important: Smartphone competition in global markets such as China could be hurting demand for the iPhone 16 along with weak reception to the Glowtime event and the new features.
With many consumers expecting more integrated AI features, the lack of AI features and slow rollout of Apple Intelligence could be a disappointment.
While it remains to be determined what the official sales figures for the iPhone 16 in 2024 and beyond are, initial iPhone 16 leaks aren't suggesting strong results.
Analysts could lower price targets and financial expectations as more data becomes available.
Pre-orders for the iPhone 16 began on Sept. 13 with initial deliveries on Sept. 20.
 AAPL Price Action: Apple stock closed Wednesday up 1.80% at $220.69 versus a 52-week trading range of $164.08 to $237.23. Apple stock is up 18.9% year-to-date in 2024.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40799397/apple-analysts-mixed-after-glowtime-event-iphone-16-could-drive-upgrades-but-next-y">Apple Analysts Mixed After Glowtime Event: iPhone 16 Could &#8216;Drive Upgrades,&#8217; But &#8216;Next Year Will Be Better&#8217;</a></li>
</ul>
Photo: Courtesy Apple

AAPL

Apple iPhone 16 Pre-Orders Show Possible Low Demand, One Sign Could Point To Company Break With This Employee Rule

Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) is set to end its work-from-home regime and mandate a return to full-time office work starting in January.&nbsp; CEO Andy Jassy shared the news to employees in a Monday memo, also announcing changes to<a href="https://www.benzinga.com/top-stories/24/09/40887347/amazon-to-cut-management-layers-end-work-from-home"> the managerial structure.</a>
The end of a flexible work-from-home mandate has a more meaningful impact for the average employee. This decision has drawn considerable attention, particularly from former employees such as John McBride, a former Amazon Web Services (AWS) software engineer, who shared his opinions in an<a href="https://x.com/johncodezzz/status/1836259845118231000"> X</a> post.
McBride, who worked at AWS for a year before resigning due to Amazon&#8217;s insistence on relocating from Denver to Seattle, believes the move to reinstate full office presence is primarily driven by economic factors — as headcount reduction helps the company boost its margin.
Amazon hired heavily in the COVID-19 aftershock, adding over 400,000 employees through 2020. McBride believes the company has overhired and since then, has gone through several phases, starting with mass layoffs and gradually implementing stricter office requirements to push employees into resigning if they refuse to relocate.
His former colleague, former AWS senior developer Justin Garrison, documented such a practice as "<a href="https://justingarrison.com/blog/2023-12-30-amazons-silent-sacking/">The Silent Sacking</a>."
Garrison explained that instead of openly laying off employees, Amazon quietly encourages them to leave by making their roles undesirable. Employees are excluded from meetings, given unfulfilling work and generally made to feel unwelcome, pushing them to quit voluntarily.
This method helps Amazon cut costs without formally announcing mass layoffs or offering severance packages. His experiences show a company that quietly subverts its employees, avoiding the public scrutiny of large-scale firings.
While the means offer a reasonably clear explanation, the ends are mixed.
McBride's claim about AWS's thin operating margins is unsubstantiated. That segment has been the most profitable, with margins reaching almost 40%.
Still, his remark on tax breaks and the office presents a more reasonable angle. In 2022, Amazon received<a href="https://qz.com/amazon-s-5-billion-discount-see-all-its-tax-cuts-and-1849821611"> at least $5 billion</a> in U.S.-based tax breaks and other subsidies from 38 states, with $824 million coming from Virginia, where the corporation has a second domestic headquarters.
The company specifically located the second headquarters there, Crystal City, which is part of Arlington, Virginia, after asking for subsidy proposals from state and local governments.
Furthermore, office-based work can positively impact local economies by supporting restaurants, transportation and other services around corporate hubs. This creates a ripple effect that benefits not just Amazon, but the broader business ecosystem in cities like Arlington.
Also Read: • <a href="https://www.benzinga.com/economics/macro-economic-events/24/09/40927293/powell-defends-0-5-interest-rate-drop-as-right-thing-for-the-economy-doubles-down">Powell Defends 0.5% Interest Rate Drop As &#8216;Right Thing For The Economy,&#8217; Doubles Down On Fed&#8217;s Cautious, Data-Driven Approach</a>
Photo: Shutterstock

Large Cap

Rumors

Management

AMZN

Amazon Ends Remote Work, Former Employee Asks If This Is The Company's Version Of 'Silent Sacking'

Billionaire investor, entrepreneur and NBA team owner Mark Cuban announced that the 16th season of "Shark Tank" <a href="https://www.benzinga.com/news/23/11/35971715/billionaire-entrepreneur-mark-cuban-set-to-leave-shark-tank-after-season-16-its-time">will be his last.</a>
With a new shark set to join the cast alongside Cuban in the 16th season, could the show be testing his replacement?
What Happened: Cuban has been a staple on "Shark Tank" since the third season and has <a href="https://www.benzinga.com/news/23/11/35988212/mark-cuban-to-exit-shark-tank-reflects-on-his-worst-deal-and-surprise-success-shared-with-benzinga">invested over $20 million</a> in companies over the numerous seasons of the award-winning investing show.
With Cuban's decision to leave, questions remain on how the show that airs on Walt Disney Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>) unit ABC will handle future seasons.
On Wednesday, the company announced that Kind Snacks founder Daniel Lubetzky will be joining the show as the first new regular investor in more than a decade, as reported by <a href="https://variety.com/2024/tv/news/shark-tank-kind-snacks-daniel-lubetzky-1236148219/">Variety</a>.
Lubetzky has previously been a guest shark on the show with appearances in Seasons 11 through 15. The billionaire has <a href="https://www.benzinga.com/startups/24/02/37102187/shark-tank-helped-retired-couple-bring-in-over-100-000-in-less-than-24-hours-after-appearing-on-the">invested in companies </a>such as Yellow Leaf Hammocks, FitFighter, Toast-It and HummViewer while on the show.
With Lubetzky as part of the regular list of panelists, it adds a billionaire who Forbes estimates his wealth at $2.3 billion. Cuban has a net worth of $5.7 billion according to Forbes.
Lubetzky <a href="https://www.benzinga.com/m-a/20/11/18428174/a-look-at-mars-latest-acquisition-kind-bars">sold Kind Snacks </a>to Mars in 2020. He now runs the investment company Camino Partners.
"It's an honor to be part of a production that continues to educate, entertain and unite Americans behind the spirit of building together," Lubetzky said.
Lubetzky said he is looking forward to "partnering with entrepreneurs from all walks of life" who are pursuing the American dream.
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent091824">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
What's Next: Lubetzky is set to join the Season 16 panel, which will include the regular rotation of sharks Cuban, Barbara Corcoran, Lori Greiner, Robert Herjavec, Daymond John and Kevin O'Leary. The season will be Cuban's last.
The show, which is produced by Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>)-owned MGM Television in association with Sony Group Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SONY#NYSE">SONY</a>) unit Sony Pictures Television doesn't show plans of slowing down despite Cuban leaving.
According <a href="https://www.nytimes.com/2024/09/18/business/daniel-lubetzky-shark-tank-mark-cuban.html">to </a>the New York Times, Lubetzky signed a multi-season deal, which likely indicates the producers' confidence in the billionaire having a big part in the show in a post-Cuban world.
"Shark Tank" executive director Clay Newbill said Lubetzky is not a direct replacement for Cuban though.
"Personally, I don't think that you can replace Mark Cuban. He's a force on the show," Newbill said.
Four new guest sharks are also being added for Season 16, including venture capitalist Rashaun Williams and Raising Cane's CEO Todd Graves.
Season 16 is set to premiere on ABC on Oct. 18.
Photo: Shutterstock

Entertainment

Media

Sony Group Corporation American Depositary Shares

SONY

Slide Over Mark Cuban, There's A New Shark In The Pool: Could This Billionaire Be His Replacement On 'Shark Tank'?

Thailand has introduced a new cannabis bill to regulate the country&#8217;s booming marijuana industry, marking the latest step in its ongoing efforts to steer cannabis use toward medical and<a href="https://www.benzinga.com/topic/medical-cannabis"> health-related purposes. </a>
This move comes after a series of policy shifts and follows the 2022 decriminalization of the plant, which made Thailand the first country in Asia to take such action.
See Also: <a href="https://www.benzinga.com/markets/cannabis/24/08/40492719/thailands-cannabis-prices-drop-amid-oversupply-and-legal-uncertainties-pakistan-senate-reviews-m">Thailand&#8217;s Cannabis Prices Drop Amid Oversupply And Legal Uncertainties</a>
The new draft bill, published earlier this week by the Ministry of Public Health, is seen as a more measured approach than previous proposals, Bloomberg <a href="https://www.bloomberg.com/news/articles/2024-09-18/thailand-unveils-new-bill-to-regulate-cannabis-while-keeping-it-legal">reported.</a>
It arrives just days after Prime Minister Paetongtarn Shinawatra's administration took office. The legislation allows cannabis and its extracts to be used for medical treatment and research by state agencies, while also approving its use in herbal remedies, food products, and cosmetics.
<h3 class="wp-block-heading">Softer Stance On Recreational Use</h3>
One key aspect of the bill is its omission of a clause that explicitly outlaws recreational cannabis use, which was part of an earlier draft under former Prime Minister Srettha Thavisin. 
The new version also abandons previous efforts to reclassify cannabis as a "narcotic," a significant shift from the original stance taken by the ruling Pheu Thai Party during last year&#8217;s national elections. 
While Pheu Thai initially vowed to restrict cannabis use to medical purposes over addiction concerns, opposition from the Bhumjaithai Party, a key coalition partner, has resulted in the plant remaining legal.
Despite this more lenient approach, penalties for those who use cannabis outside the bill's defined uses remain steep. 
Under the current draft, individuals caught using cannabis for purposes not specified in the legislation will face fines of up to 60,000 baht (approximately $1,803). Sellers of cannabis products not adhering to the law face even harsher penalties, including a possible one-year jail term, fines of up to 100,000 baht, or both.
<h3 class="wp-block-heading">Impacts On Thailand's Cannabis Boom</h3>
Thailand&#8217;s decriminalization of cannabis in 2022 led to the rapid rise of more than 9,400 cannabis dispensaries across the country, especially in popular tourist destinations and business hubs such as Bangkok. 
With this new bill, the government seeks to bring tighter control over this growing industry, requiring all cannabis growers, sellers and related businesses to apply for licenses or permits. Failure to comply could result in hefty fines or jail terms.
The draft legislation also calls for stricter regulations on the planting, sale, export and import of cannabis. Businesses that produce cannabis-infused goods, such as candies and baked goods, will be required to adhere to the current law, which mandates that these products contain no more than 0.2% THC, the psychoactive compound responsible for cannabis' "high" effect.
The public and industry stakeholders have until September 30 to submit their feedback on the draft legislation. The Ministry of Public Health will review the input and may make changes before presenting the bill to the cabinet. From there, it will head to parliament for approval, where it could still face further debate and revisions.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/asia/24/09/40832311/inside-the-thai-retreat-with-cannabis-infused-wellness-treatments-that-target-insomnia-and-more">Inside The Thai Retreat With Cannabis-Infused Wellness Treatments That Target Insomnia And More</a></li>
</ul>
Cover image made with AI.

Asia

Cannabis

Thailand's New Cannabis Bill: Stricter Rules, But Marijuana Remains Legal

A significant Ukrainian drone assault on Russia caused an <a href="https://www.benzinga.com/government/24/09/40888451/russia-to-expand-army-for-third-time-since-war-with-ukraine-began-defense-stocks-rtx-northrop-grumma">earthquake-sized eruption</a> at a major arsenal in the Tver region on Wednesday, forcing citizens in the city of Toropets to evacuate, according to reports from war bloggers and some media.
Unverified video and images on social media showed a huge ball of flame rising into the night sky and numerous explosion detonations tearing across a lake about 240 miles west of Moscow, Reuters reported.
NASA satellites registered intense heat sources coming from an area of about five square miles at the site in the early hours. Earthquake monitoring stations picked up the attack as a small earthquake&nbsp;in the area.
&#8220;The enemy hit an ammunition depot in the area of Toropets,&#8221; said Yuri Podolyaka, a Ukrainian-born, pro-Russian military blogger. &#8220;Everything that can burn is already burning there (and exploding).&#8221;
Read Also: <a href="http://US And Allies Worried Amid Reports Of Russia Potentially Sharing Nuclear Secrets With Iran">US And Allies Worried Amid Reports Of Russia Potentially Sharing Nuclear Secrets With Iran</a>
Ukrainian President Volodymyr Zelenskyy, speaking in his nightly video address, praised the attack without mentioning the target.
&#8220;A very important result was achieved last night on Russian territory and such actions weaken the enemy,&#8221; Zelenskyy said. &#8220;I thank everyone involved. Such precision is truly inspiring.&#8221;
A source in Ukraine&#8217;s SBU state security service told Reuters earlier that the drone attack had destroyed&nbsp;a warehouse storing missiles, guided bombs and artillery ammunition.
Igor Rudenya, governor of the Tver region, said Ukrainian drones had been shot down, a fire had broken out and some residents were being evacuated. He did not say what was burning, Reuters reported.
The size of the main blast shown in the unverified social media video was consistent with 200 to 240 tons of high explosives detonating, said George William Herbert of the Middlebury Institute of International Studies at Monterey in California.
Some war bloggers asked how drones could trigger such large blasts at what was thought to be a highly fortified facility.
Price Action: Defense contractors saw gains and losses by the end of Wednesday&#8217;s trading day.
<ul>
<li>General Dynamics Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GD#NYSE">GD</a>) slipped 0.44% to $302.52</li>
<li>Northrop Grumman Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOC#NYSE">NOC</a>) rose 0.2% to $521.77</li>
<li>TransDigm Group Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDG#NYSE">TDG</a>) declined 0.12% to $1,273.80</li>
</ul>
Exchange-traded funds that hold defense stocks trended up and down.
<ul>
<li>IShares U.S. Aerospace &amp; Defense ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ITA#BATS">ITA</a>) rose 0.06%</li>
<li>Invesco Aerospace &amp; Defense ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PPA#NYSE">PPA</a>) fell 0.13%</li>
<li>SPDR S&amp;P Aerospace &amp; Defense ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XAR#NYSE">XAR</a>) declined 0.01%</li>
</ul>
Read Now:
<ul>
<li><a href="http://over-30-months-of-war-zelensky">Russia Launches &#8216;One Of The Heaviest Strikes&#8217; On Ukraine In Over 30 Months Of War: Zelensky</a></li>
</ul>
Photo: Shutterstock

Global

iShares Dow Jones US Aerospace & Defense Index Fund

Ukrainian Drone Attack Causes Earth-Rattling Blast In Russia's Tver Region

CTSH

mecwacare, Cognizant Embark On Multi-year Relationship To Launch Digital Transformation Program

This will result in Vistra being the sole owner of its Vistra Vision subsidiary, which includes its zero-carbon nuclear, energy storage, and solar generation assets, as well as its retail business.
The net present value of the purchase price as of&nbsp;Dec. 31, 2024, discounted at a&nbsp;6%&nbsp;interest rate, is&nbsp;$3.085 billion.
The agreement does not impact or change Vistra&#39;s capital allocation priorities. Vistra remains committed to its long-term net leverage target of less than 3x2. Vistra also continues to expect to execute at least&nbsp;$2.25 billion&nbsp;of share repurchases in 2024 and 2025 and at least&nbsp;$1 billion&nbsp;in 20263, as well as pay&nbsp;$300 million&nbsp;in aggregate common dividends in each year 2024-20263.
&nbsp;

Vistra Enters Deal With Nuveen Asset Management And Avenue Capital To Acquire Their Combined 15% Equity Interest In Vistra Vision LLC For Undiscounted Purchase Price Of $3.248B Cash, To Be Paid In Five Installments

BLMZ

BloomZ Gets Nasdaq Notification Letter That It Is Not In Compliance With Minimum Market Value Requirement

Core Scientific, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORZ#NASDAQ">CORZ</a>) shares moved higher Wednesday as markets witnessed the first interest rate cut from the <a href="https://www.benzinga.com/economics/macro-economic-events/24/09/40926026/federal-reserve-delivers-bold-0-5-rate-cut-signals-further-easing-ahead">Federal Reserve in four years. </a>
The Details: Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) miner Core Scientific's stock has climbed more than 20% over the past five days, as investors anticipated an interest rate cut. 
The Federal Reserve announced a 50 basis points (bps) cut Wednesday, bringing the federal funds rate down to a range of 4.75%-5% and increasing the appeal of risk assets like stocks and cryptocurrencies. 
Core Scientific shares climbed throughout Wednesday's session and spiked to an intraday high of $12.48  just after the announcement from Fed Chairman Jerome Powell. 
Read Next: <a href="https://www.benzinga.com/news/large-cap/24/09/40910569/nvidia-salesforce-announce-strategic-ai-collaboration-what-to-know">NVIDIA, Salesforce Announce Strategic AI Collaboration: What To Know</a>
Earlier this month, Core Scientific CEO Adam Sullivan shared plans with Bernstein analysts to <a href="https://www.benzinga.com/top-stories/24/09/40800336/core-scientific-aims-for-25-30-billion-valuation-with-ai-data-center-services-bernstein">significantly expand</a> the company's AI data center services, potentially boosting its valuation to a range of $25 billion to $30 billion.&nbsp;
According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Core Scientific shares are trading above the stock&#8217;s 50-day moving average of $10.05 and just under its 52-week high of $12.25.&nbsp;
CORZ Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Core Scientific shares ended Wednesday's session up 4.79% at $12.03.&nbsp;
Read Also:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/09/40904271/whats-going-on-with-amazon-stock">What&#8217;s Going On With Amazon Stock?</a></li>
</ul>
Photo: Shutterstock

Core Scientific, Inc. - Class A Common Stock

CORZ

What Happened With Bitcoin Miner Core Scientific's Stock Today?

Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) shares are moving higher Wednesday. Here&#8217;s <a href="https://www.benzinga.com/news/24/09/40917539/while-apple-abandoned-its-car-project-after-pouring-1b-into-it-its-key-supplier-foxconn-is-now-colla">what you need to know.</a>
What To Know: In significant economic development, the Federal Reserve instituted a<a href="https://www.benzinga.com/economics/macro-economic-events/24/09/40927293/powell-defends-0-5-interest-rate-drop-as-right-thing-for-the-economy-doubles-down"> 50 basis points cut</a>, bringing the federal funds rate to 4.75%–5%. This unexpected move, marking the first rate reduction in more than four years, reflects the Fed&#8217;s greater confidence in managing inflation. 
The Fed also revised its economic growth forecast for 2024 down to 2%. Inflation projections for the same year were also lowered, while unemployment rates were revised upward through 2026.
Future Rate Path: The updated Dot Plot suggests another 50 basis points in cuts in 2024 and an additional 100 basis points by the end of 2025, highlighting a more aggressive easing approach compared to previous projections. This outlook signals a significant shift from the Fed's earlier stance and impacts projections for economic metrics over the next few years.
See Also:<a href="https://www.benzinga.com/economics/macro-economic-events/24/09/40927293/powell-defends-0-5-interest-rate-drop-as-right-thing-for-the-economy-doubles-down"> Powell Defends 0.5% Interest Rate Drop As &#8216;Right Thing For The Economy,&#8217; Doubles Down On Fed&#8217;s Cautious, Data-Driven Approach</a>
What Else: The company formerly abandoned its electric vehicle (EV) project after significant investments. In contrast, its key supplier Hon Hai Precision Industry Co Ltd &#8211; ADR, also known as Foxconn, (OTC:<a class="ticker" href="https://www.benzinga.com/stock/HNHPF#OTC">HNHPF</a>) is advancing in the EV market. Foxconn, collaborating with Sharp, recently unveiled the LDK+ electric vehicle prototype. Designed with a room-like interior, the LDK+ aims to serve as a personal space, highlighting the evolving role of vehicles in the autonomous driving era.
Foxconn demonstrated strategic acumen by focusing on modular EV platforms that allow for cost-efficient, unique model creation. The company has also approved a $246 million investment in Northern Vietnam for manufacturing EV parts, with operations expected to start in January 2025. This investment underscores Foxconn's commitment to enhancing its production capabilities and positioning itself as a notable player in the EV industry.
AAPL Price Action: Apple shares closed Wednesday up 1.80% at $220.69, according to <a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2">Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><a href="https://benzinga.slack.com/archives/D072651PB4K/p1722883001180099"><img loading="lazy" decoding="async" width="1024" height="548" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/18141238/AAPL-1-1024x548.png" alt="" class="wp-image-554734" style="width:482px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/18141238/AAPL-1-1024x548.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/18141238/AAPL-1-300x161.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/18141238/AAPL-1-768x411.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/18141238/AAPL-1.png 1078w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/09/40925721/crowdstrike-launches-ai-security-posture-management-to-enhance-cloud-protection">CrowdStrike Launches AI Security Posture Management To Enhance Cloud Protection</a></li>
</ul>
Photo: Courtesy Apple Inc.

After-Hours Center

HNHPF

Apple Shares Are Trading Higher Today: What You Need To Know

INCY

SNDX

Incyte, Syndax Report Publication Of Data From Pivotal AGAVE-201 Trial Of Niktimvo; Trial Met The Primary Endpoint Across All Cohorts

Northrop Grumman Says B-21 Raider Program Is Making Progress As The Team Executes Flight Test Campaign And Scales Into Production

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Joby Aviation (NYSE:<a href="https://investorplace.com/stock-quotes/joby-stock-quote/">JOBY</a>) stock is flying higher on Thursday after the electric vertical takeoff and landing (eVTOL) company <a href="https://finance.yahoo.com/news/joby-demonstrates-potential-emissions-free-100000388.html">reported a new milestone</a> for its aircraft.



According to a press release from Joby Aviation, it completed a massive 523-mile-long eVTOL flight. This flight was made with an aircraft running off of a combination of electricity and hydrogen. The company notes the only byproduct of the flight was water.



It also highlights that this will allow for much longer transits than what&rsquo;s possible with just an electric aircraft. It uses trips between San Francisco to San Diego, Boston to Baltimore, and Nashville to New Orleans as examples of this.



<h2>What&rsquo;s Next for JOBY Stock</h2>



JoeBen Bevirt, Founder and CEO of Joby Aviation, said the following about the news and how it affects the company.




&ldquo;The vast majority of the design, testing and certification work we&rsquo;ve completed on our battery-electric aircraft carries over to commercializing hydrogen-electric flight. In service, we also expect to be able to use the same landing pads, the same operations team, and Joby&rsquo;s ElevateOS software that will support the commercial operation of our battery-electric aircraft.&rdquo;




JOBY stock is up 16% as of Thursday afternoon. However, the shares are still down 1.9% year-to-date.



We have more of the most recent stock market stories traders need to know about on Thursday!



InvestorPlace is home to all of the hottest stock market news today! That includes what&rsquo;s going on with shares of Kazia Therapeutics&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/kzia-stock-quote/">KZIA</a>) stock, MicroStrategy&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/mstr-stock-quote/">MSTR</a>) stock and Biodexa Pharmaceuticals&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/bdrx-stock-quote/">BDRX</a>) stock today. You can catch up on all of that at the links below!



<h2>More Stock Market News for Thursday</h2>



<ul><li><a href="https://investorplace.com/2024/07/kzia-stock-alert-kazia-continues-its-surge-on-thursday-with-51-gains/">KZIA Stock Alert: Kazia Continues Its Surge on Thursday With 51% Gains</a></li>



<li><a href="https://investorplace.com/2024/07/mstr-stock-alert-get-ready-for-a-10-for-1-microstrategy-stock-split/">MSTR Stock Alert: Get Ready for a 10-for-1 MicroStrategy Stock Split</a></li>



<li><a href="https://investorplace.com/2024/07/why-is-biodexa-pharmaceuticals-bdrx-up-56-today/">Why Is Biodexa Pharmaceuticals (BDRX) Up 56% Today?</a></li>
</ul>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/07/joby-stock-pops-after-completing-523-mile-evtol-flight/">JOBY Stock Pops After Completing 523-Mile eVTOL Flight</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

JOBY Stock Pops After Completing 523-Mile eVTOL Flight

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Silk recalls are a hot topic on Thursday as the plant-based milk alternative is being pulled from shelves <a href="https://www.foodsafetynews.com/2024/07/illnesses-prompt-nationwide-recall-of-silk-and-great-value-brand-plant-based-beverages-in-canada/">due to listeria monocytogenes&nbsp;concerns</a>.



This recall affects Silk products and Walmart&rsquo;s (NYSE:<a href="https://investorplace.com/stock-quotes/wmt-stock-quote/">WMT</a>) Great Value products sold in Canada. An outbreak of foodborne illness resulted in an investigation that spurred the recall. It&rsquo;s also possible this recall could spread to more products made by Danone Canada.



Consumers are advised not to consume, use, sell, serve or distribute products included in the recall.



Let&rsquo;s <a href="https://recalls-rappels.canada.ca/en/alert-recall/various-silk-and-great-value-brand-plant-based-refrigerated-beverages-recalled-due#tablefield-node-75799-field_affected_products-0">break down the products</a> included in these recalls below!



<h2>Silk Recalls 2024: Products Affected</h2>



First up are the Silk brand products included in the recall. They include the following with best-by dates up to 24 OC 04.



<ul><li>Almond &amp; Coconut Unsweetened with UPC 0 25293 00250 0.</li>



<li>Almond Original with UPC 0 25293 00100 8.</li>



<li>Almond Dark Chocolate with UPC 0 25293 00135 0.</li>



<li>Almond Unsweetened with UPC 0 25293 00150 3.</li>



<li>Almond Unsweetened Vanilla with UPC 0 25293 00188 6.</li>



<li>Almond Vanilla with UPC 0 25293 00168 8.</li>



<li>Coconut Original with UPC 0 25293 00152 7.</li>



<li>Coconut Unsweetened with UPC 0 25293 00244 9.</li>



<li>Oat Original with UPC 0 36632 07240 5.</li>



<li>Oat Vanilla with UPC 0 36632 07241 2.</li>



<li>Oat Dark Chocolate with UPC 0 36632 07239 9.</li>



<li>Oat Unsweetened with UPC 0 36632 07532 1.</li>



<li>Oat Unsweetened Vanilla with UPC 0 56800 72749 4.</li>



<li>Almond &amp; Cashew Unsweetened with UPC 0 36632 07235 1.</li>



<li>Almond &amp; Cashew Unsweetened Vanilla with UPC 0 36632 07234 4.</li>
</ul>Now let&rsquo;s get into those Great Value brand recalls. These have the same best-by dates as the products in the Silk recalls.



<ul><li>Almond Beverage Unsweetened Original with UPC 6 81131 34208 7.</li>



<li>Almond Beverage Original with UPC 6 81131 34209 4.</li>



<li>Almond Beverage Vanilla with UPC 6 81131 34210 0.</li>
</ul>Outside of the Silk recalls, we also have stock market stories worth reading about today.



InvestorPlace is home to all of the hottest stock market stories on Thursday! Among that is what&rsquo;s going on with shares of FuelCell Energy&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/fcel-stock-quote/">FCEL</a>), Joby Aviation&nbsp;(NYSE:<a href="https://investorplace.com/stock-quotes/joby-stock-quote/">JOBY</a>) and Kazia Therapeutics&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/kzia-stock-quote/">KZIA</a>) stock. You can find out more on these matters at the following links!



<h2>More Thursday Stock Market News</h2>



<ul><li><a href="https://investorplace.com/2024/07/fcel-stock-alert-fuelcell-energy-pops-on-korean-market-update/">FCEL Stock Alert: FuelCell Energy Pops on Korean Market Update</a></li>



<li><a href="https://investorplace.com/2024/07/joby-stock-pops-after-completing-523-mile-evtol-flight/">JOBY Stock Pops After Completing 523-Mile eVTOL Flight</a></li>



<li><a href="https://investorplace.com/2024/07/kzia-stock-alert-kazia-continues-its-surge-on-thursday-with-51-gains/">KZIA Stock Alert: Kazia Continues Its Surge on Thursday With 51% Gains</a></li>
</ul>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/07/silk-recalls-2024-what-to-know-as-plant-based-milk-recalled-over-listeria-concerns/">Silk Recalls 2024: What to Know as Plant-Based Milk Recalled Over Listeria Concerns</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Silk Recalls 2024: What to Know as Plant-Based Milk Recalled Over Listeria Concerns

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Pre-market stock movers are worth keeping an eye on and we have a breakdown of all the biggest ones to watch on Friday!



Moving stocks are mergers, clinical trial data, public offerings and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Crown LNG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGBS#NASDAQ">CGBS</a>) stock is rocketing almost 154% after <a href="https://finance.yahoo.com/news/crown-lng-holding-announces-completion-201700767.html">recently completing a business combination</a>.</li>



<li>Toyo (NASDAQ:<a href="https://investorplace.com/stock-quotes/toyo-stock-quote/">TOYO</a>) shares are soaring close to 111% alongside heavy pre-market trading.</li>



<li>Sentage (NASDAQ:<a href="https://investorplace.com/stock-quotes/sntg-stock-quote/">SNTG</a>) stock is surging over 60% with strong early morning trading.</li>



<li>Above Food Ingredients (NASDAQ:<a href="https://investorplace.com/stock-quotes/abve-stock-quote/">ABVE</a>) shares are increasing more than 42% without any clear news this morning.</li>



<li>Monterey Capital Acquisition (NASDAQ:<a href="https://investorplace.com/stock-quotes/mcac-stock-quote/">MCAC</a>) stock is gaining over 23% on Friday morning.</li>



<li>Maxeon Solar Technologies (NASDAQ:<a href="https://investorplace.com/stock-quotes/maxn-stock-quote/">MAXN</a>) shares are rising more than 19% with heavy early morning trading.</li>



<li>Qualigen Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/qlgn-stock-quote/">QLGN</a>) stock is heading nearly 16% higher with strong pre-market trading.</li>



<li>Immutep (NASDAQ:<a href="https://investorplace.com/stock-quotes/immp-stock-quote/">IMMP</a>) shares are climbing over 15% with <a href="https://www.nasdaq.com/market-activity/stocks/immp/press-releases">positive clinical results</a>.</li>



<li>Big Tree Cloud (NASDAQ:<a href="https://investorplace.com/stock-quotes/dsy-stock-quote/">DSY</a>) stock is jumping more than 14% on Friday.</li>



<li>Instil Bio (NASDAQ:<a href="https://investorplace.com/stock-quotes/til-stock-quote/">TIL</a>) shares are up over 14% today.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Shineco (NASDAQ:<a href="https://investorplace.com/stock-quotes/sisi-stock-quote/">SISI</a>) stock is crashing more than 44% on a <a href="https://www.nasdaq.com/press-release/shineco-announces-proposed-underwritten-public-offering-2024-07-11">proposed public offering</a>.</li>



<li>ASP Isotopes (NASDAQ:<a href="https://investorplace.com/stock-quotes/aspi-stock-quote/">ASPI</a>) shares are diving over 19% as it also announces a <a href="https://www.globenewswire.com/news-release/2024/07/11/2912107/0/en/ASP-Isotopes-Announces-Proposed-Public-Offering-of-Common-Stock.html">proposed public offering</a>.</li>



<li>Cyngn (NASDAQ:<a href="https://investorplace.com/stock-quotes/cyn-stock-quote/">CYN</a>) stock is tumbling 18% following a <a href="https://www.nasdaq.com/press-release/more-1bn-annual-sales-alta-equipment-group-joins-cyngns-dealer-network-2024-07-11">massive rally yesterday</a>.</li>



<li>Kazia Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/kzia-stock-quote/">KZIA</a>) shares are retreating more than 16% <a href="https://investorplace.com/2024/07/kzia-stock-alert-kazia-continues-its-surge-on-thursday-with-51-gains/">after rallying this week</a>.</li>



<li>Nano Nuclear Energy (NASDAQ:<a href="https://investorplace.com/stock-quotes/nne-stock-quote/">NNE</a>) stock is taking an over 12% beating after <a href="https://www.nasdaq.com/press-release/nano-nuclear-energy-announces-pricing-upsized-18-million-underwritten-offering-2024">pricing an upsized underwritten offering</a>.</li>



<li>Biodexa Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/bdrx-stock-quote/">BDRX</a>) shares are falling more than 10% after jumping yesterday on <a href="https://seekingalpha.com/news/4123698-biodexa-stock-rallies-amid-release-of-phase-2-data-for-erapa">clinical trial data</a>.</li>



<li>Digital Brands Group (NASDAQ:<a href="https://investorplace.com/stock-quotes/dbgi-stock-quote/">DBGI</a>) stock is dropping over 10% this morning.</li>



<li>Sonoma Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/snoa-stock-quote/">SNOA</a>) shares are decreasing more than 10% following a Thursday rally.</li>



<li>Forward Industries (NASDAQ:<a href="https://investorplace.com/stock-quotes/ford-stock-quote/">FORD</a>) stock is dipping 10% without any news to report.</li>



<li>Nuwellis (NASDAQ:<a href="https://investorplace.com/stock-quotes/nuwe-stock-quote/">NUWE</a>) shares close out our pre-market stock movers down over 9% this morning.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/07/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-friday-july-12th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
If you&rsquo;ve read all the warnings and still want to jump into some of the top <a href="https://investorplace.com/stock-types/penny-stocks/">penny stocks</a> to buy, focus on the key fundamentals.



That includes its earnings numbers, business models, product pipelines and what market they&rsquo;re part of.&nbsp;



You&rsquo;ll also want to pay close attention to volume, especially volume spikes. That&rsquo;s because volume often precedes price. In addition, you&rsquo;ll also want to see if the volume is being supported by news. Or you&rsquo;ll get what we just saw with Zapp Electric (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZAPP#NASDAQ">ZAPP</a>).



Over the last few days, ZAPP ran from about $2 to $19.10 on heavy volume &mdash; but no news.



On July 2, it traded at $2.04 and saw volume spike to 35.2 million, as compared to average volume of 7.2 million. On July 3, volume jumped to 25.5 million.



By July 5, it was up to 50.3 million. Then by July 8, volume soared to 105 million. And by July 9, volume was up 45 million. Now, as volume fades, the stock is starting to pull back.&nbsp;While it was fun to watch, it won&rsquo;t end well &mdash; especially for the stock-chasing bag holders.



Here are a few &ldquo;safer&rdquo; penny stocks to buy instead.



<h2>Kazia Therapeutics (KZIA)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/03/pharmaceuticals_tnxp_1600-300x169.png" alt="medicine research, pharmaceutical background, LJPC stock"><div>Source: Sisacorn / Shutterstock.com</div></div>Keep an eye on penny stocks to buy such as Kazia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KZIA#NASDAQ">KZIA</a>). Even after exploding from 20 cents to a high of $1.08, it could push aggressively higher.&nbsp;



All after it posted <a href="https://www.biospace.com/article/releases/kazia-therapeutics-announces-phase-ii-iii-clinical-trial-results-for-paxalisib-in-glioblastoma/">positive Phase 2/3 results</a> for its drug paxalisib in the treatment of glioblastoma, which is a malignant tumor affecting the brain or spine. The study, called GBM-AGILE, showed a median overall survival of&nbsp;14.77 months for paxalisib-treated patients, as compared to 13.84 months for those given the standard of care.



With that, the company said it will request a meeting with the U.S. FDA to see if it can get accelerated approval.&nbsp;



As noted by <a href="https://www.biospace.com/article/releases/kazia-therapeutics-announces-phase-ii-iii-clinical-trial-results-for-paxalisib-in-glioblastoma/">Kazia CEO&nbsp;Dr.&nbsp;John Friend</a>, &ldquo;We are excited to have shown a 3.8-month improvement in overall survival, an approximate 33% improvement, for newly diagnosed unmethylated patients with GBM compared to the concurrent standard of care arm. Having comparable Overall Survival data across two independent studies is a compelling outcome in this difficult-to-treat glioblastoma population.&rdquo;



<h2>Curaleaf Holdings (CURLF)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/04/cannabis-stocks1600-3-300x169.png" alt="scientist checking organic hemp wild plants in a cannabis weed commercial greenhouse. Concept of herbal alternative medicine, cbd oil, pharmaceutical industry. Cannabis stocks, FLGC stocks"><div>Source: Chokniti-Studio / Shutterstock.com</div></div>At a bit over $4, Curaleaf Holdings (OTCMKTS:<a href="https://investorplace.com/stock-quotes/curlf-stock-quote/">CURLF</a>) is a strong buy on three key cannabis catalysts.



As I noted on July 8, &ldquo;We already know&nbsp;<a href="https://www.pewresearch.org/short-reads/2024/04/10/facts-about-marijuana/#:~:text=An%20overwhelming%20majority%20of%20U.S.,and%20recreational%20use%20(57%25).">88% of Americans</a>&nbsp;want legalization, which the current candidates should use to their advantage for votes. We know cannabis will be rescheduled as a Schedule III drug at some point.&nbsp;And we know that Florida will vote on legalization.&rdquo;



If Florida votes for legalization, it could unlock a massive market opportunity. All are potentially powerful catalysts.



Helping,&nbsp;<a href="https://www.newcannabisventures.com/curaleaf-q1-revenue/">according to Curaleaf CEO Matt Darin</a>, &ldquo;Our unique exposure to the most significant catalysts on the horizon &mdash; continued expansion of the NY market, expansion of Pillar 1 in&nbsp;Germany, and adult use in&nbsp;Ohio,&nbsp;Florida and&nbsp;Pennsylvania&nbsp;sets us up for robust growth in 2025 and beyond.&rdquo;



Last trading at around $4.16, I&rsquo;d use the recent weakness as an opportunity as we near the election.



<h2>Plug Power (PLUG)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/03/plug1600-7-300x169.png" alt="In this photo illustration, the Plug Power logo is displayed on a smartphone screen"><div>Source: rafapress / Shutterstock.com</div></div>We can also look at down, but not out shares of hydrogen stock, Plug Power (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLUG#NASDAQ">PLUG</a>).



After finding strong support at around $2.21, PLUG now trades at $3.02 and could push higher.&nbsp;Helping, the company just&nbsp;<a href="https://www.ir.plugpower.com/press-releases/news-details/2024/Plug-Completes-13-Hydrogen-Refueling-Station-Deployments-Over-Last-Two-Years-in-Europe/default.aspx#:~:text=SLINGERLANDS%2C%20N.Y.%2C%20July%2010%2C,last%20two%20years%20across%20Europe.">deployed 13 hydrogen refueling stations across Europe.</a> While most are still in the commissioning phase, all are expected to be operational this summer.



Even better, the company said it saw a &ldquo;<a href="https://seekingalpha.com/news/4092367-plug-power-touts-substantial-advancement-in-hydrogen-generation-buildout">substantial advancement</a>&rdquo; with its plants in Georgia and Tennessee. It also noted that its Louisiana joint venture with&nbsp;Olin&nbsp;(NYSE:<a href="https://investorplace.com/stock-quotes/oln-stock-quote/">OLN</a>) is on track to see mechanical completion by the end of the third quarter.



Plus, it just signed&nbsp;<a href="https://www.globenewswire.com/news-release/2024/04/25/2869470/9619/en/Plug-Signs-Additional-BEDP-Contracts-for-a-Total-of-4-5GW-of-Electrolyzers-Across-Europe-and-the-United-States.html">two contracts</a>&nbsp;to deliver basic engineering and design packages for projects in Europe and the U.S.



Moreover, when and if we see changes to restrictive 45V industry tax credits, Plug Power and other top <a href="https://investorplace.com/industries/energy/renewable-energy/hydrogen/">hydrogen stocks</a> could race to higher highs.



On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions,&nbsp;InvestorPlace&nbsp;does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s&nbsp;writers disclose this fact and warn readers of the risks.



Read More:&#8239;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">Penny Stocks &mdash;&nbsp;How to Profit Without Getting Scammed</a>



On the date of publication, Ian Cooper did not hold (either directly or indirectly) any positions in the securities mentioned. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/?utm_source=Nasdaq&amp;utm_medium=referral">Publishing Guidelines</a>.



On the date of publication, the responsible editor did not have (either directly or indirectly) any positions in the securities mentioned in this article.
<div>Ian Cooper, a contributor to InvestorPlace.com, has been analyzing stocks and options for web-based advisories since 1999.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/2024/07/from-pennies-to-dollars-3-sub-5-stocks-set-to-explode-higher/">From Pennies to Dollars: 3 Sub-$5 Stocks Set to Explode Higher</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

From Pennies to Dollars: 3 Sub-$5 Stocks Set to Explode Higher

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Biotechnology stock traders, listen up! Do you like to roll the dice and take your chances on promising drug developers? If so, then you&rsquo;ll definitely want to add Kazia Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/kzia-stock-quote/">KZIA</a>) to your watch list. I can&rsquo;t guarantee any safety whatsoever, but Kazia Therapeutics stock offers excitement and the possibility of substantial profits.



Or, Kazia Therapeutics might not secure full regulatory approval for its primary product, and the stock could go nowhere or just go to zero. Nearly any outcome is plausible in the wild world of <a href="https://investorplace.com/industries/healthcare/biotech/">biotech stocks</a>. So, I invite you to discover Kazia Therapeutics and decide if your stomach can handle the volatility and unpredictability.



<h2>Why Kazia Therapeutics Stock Went Bananas</h2>



Just to recap, Australian biotechnology business Kazia Therapeutics develops oncology (cancer and tumor fighting) drugs. One of Kazia Therapeutics&rsquo; drug-development programs is <a href="https://finance.yahoo.com/news/kazia-therapeutics-announces-phase-ii-113000064.html">EVT801</a>. This was found in preclinical research to be &ldquo;active against a broad range of tumour types.&rdquo;



Not to discount the importance of EVT801, but Kazia Therapeutics&rsquo; primary drug in development is <a href="https://finance.yahoo.com/news/kazia-therapeutics-announces-phase-ii-113000064.html">paxalisib</a>. Recently, Kazia Therapeutics completed a phase II/III study of paxalisib in the treatment of a type of brain cancer type called glioblastoma.



Kazia Therapeutics CEO John Friend&nbsp;proudly announced the results of the clinical trial. Paxalisib demonstrated a &ldquo;3.8 month improvement in overall survival, an approximate 33% improvement&rdquo; for selected glioblastoma patients when &ldquo;compared to the concurrent standard of care arm.&rdquo;



Furthermore, Kazia Therapeutics was well tolerated in the study. Thus, this is huge news for Kazia Therapeutics as paxalisib is the company&rsquo;s flagship product.



Kazia Therapeutics stock skyrocketed from 20 cents per share to a 52-week high of $1.58. However, the stock then sank to 53 cents. By the time you read this, the share price may be much higher or lower than that.



<h2>What&rsquo;s Next for Kazia Therapeutics?</h2>



I expect the Kazia Therapeutics share price to level off as the buyers and sellers start to calm down in the coming days. Going forward, investors should consider what&rsquo;s next for Kazia Therapeutics and paxalisib.



Two events could be make-or-break for Kazia Therapeutics. First of all, Kazia Therapeutics expects to release the full data from the paxalisib research study &ldquo;at a scientific meeting later this year.&rdquo; Heaven only knows when this will actually take place, so I won&rsquo;t attempt to make any predictions.



Kazia Therapeutics stated that it will request a meeting with the U.S. Food and Drug Administration to &ldquo;discuss the results and determine if a potential path to accelerated approval is appropriate for paxalisib.&rdquo; 



Full FDA approval is the gold standard for proposed drugs in the U.S., so keep an eye out for further developments on this news story.



<h2>Kazia Therapeutics Stock: Predict Nothing and Protect Your Wealth</h2>



Some stock traders probably enjoyed quick gains after Kazia Therapeutics released its positive clinical-trial results. Yet, some ill-timed traders may have lost money. It just goes to show that biotech stocks can be highly unpredictable and risky.



Hence, I don&rsquo;t recommend trying to predict with 100% confidence whether Kazia Therapeutics will get full FDA approval for paxalisib in treating glioblastoma patients. 



Instead, if you appreciate the company&rsquo;s promising clinical work, consider buying Kazia Therapeutics stock. At the same time, be sure to protect your wealth by only taking a very small share position.



On the date of publication, David Moadel&nbsp;did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.



On the date of publication, the responsible editor did not have (either directly or indirectly) and positions in the securities mentioned in this article.
<div>David Moadel has provided compelling content &ndash; and crossed the occasional line &ndash; on behalf of Motley Fool, Crush the Street, Market Realist, TalkMarkets, TipRanks, Benzinga, and (of course) InvestorPlace.com. He also serves as the chief analyst and market researcher for Portfolio Wealth Global and hosts the popular financial YouTube channel Looking at the Markets.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/07/biotech-stock-laboratory-try-a-small-experiment-with-kazia-therapeutics/">Biotech Stock Laboratory: Try a Small Experiment With Kazia Therapeutics</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Biotech Stock Laboratory: Try a Small Experiment With Kazia Therapeutics

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Australian biotech company Kazia Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/kzia-stock-quote/">KZIA</a>) stock rocked the market after reporting encouraging results from a Phase II/III trial for its glioblastoma brain cancer therapy Paxalisib.&nbsp;



The positive results extended the life of patients by over three months compared to the current standard of care. Because the patients were a difficult-to-treat population, the results gave the oncology biotech developer cause to arrange a meeting with the Food &amp; Drug Administration (FDA) to pursue an accelerated pathway for approval.



As a result, Kazia Therapeutics stock surged 730% on the news, jumping from 19 cents per share to as high as $1.58 before eventually tumbling lower. Shares stand 110% above where they traded before it posted the results.



Because glioblastoma treatment is seen as a <a href="https://www.pharmiweb.com/press-release/2024-03-25/glioblastoma-treatment-market-expected-to-reach-usd-103-billion-by-2032-marketresearchbiz">$10 billion market opportunity</a> according to some estimates, producing a treatment that is better than the current level of care is a major achievement.&nbsp;



As such, there are numerous avenues for Kazia Therapeutics to exploit this market if Paxalisib gains approval. What can&rsquo;t be ignored is the possibility a pharmaceutical giant that is looking to bolster its portfolio of oncology drugs could step up and acquire Kazia Therapeutics stock.



<h2>A New Lease on Life</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/02/cells-microscope-300x169.png" alt="An image of cells under a microscope"><div>Source: pinkeyes/Shutterstock</div></div>Glioblastoma (GBM) is reportedly <a href="https://www.aans.org/patients/conditions-treatments/glioblastoma-multiforme/">one of the most common</a> and aggressive forms of brain cancer. It represents nearly half of all brain cancers. Tumors form in the brain or spinal cord though they most often occur in the frontal and temporal lobes. Left untreated, GBM can be fatal in six months or less.



Kazia Therapeutics&rsquo; Paxalisib is its<a href="https://www.prnewswire.com/news-releases/kazia-therapeutics-announces-phase-iiiii-clinical-trial-results-for-paxalisib-in-glioblastoma-302193414.html"> lead drug candidate</a> and has been the subject of 10 clinical trials for this disease. The FDA previously granted the therapy Orphan Drug status in 2018 and it gained fast-track designation in 2020. It has received various other designations from the regulatory authorities for various diseases.



In the Phase II/III study, Paxalisib resulted in a median survival rate of over 15.5 months compared to 11.9 months under the current standard of care. This is in line with an earlier Phase II study that found similar longevity by administering Paxalisib.



<h2>A Hotbed of M&amp;A Activity</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/10/mergers-acquisitions-300x169.jpg" alt='The letters "M&amp;A" on a wooden table, surrounded by a calculator and other business items. Representing IEA stock.'><div>Source: Shutterstock.com</div></div>According to analysts at White &amp; Case, the field of oncology is setting a fire underneath mergers and acquisitions. Dealmaking will <a href="https://mergers.whitecase.com/highlights/oncology-dealmaking-fuels-biotech-ma#!">reach $375 billion</a> in 2027 as demand for treatments grows.



In less than a year, Bristol Myers Squibb (NYSE:<a href="https://investorplace.com/stock-quotes/bmy-stock-quote/">BMY</a>) acquired Mirati Therapeutics for $5.8 billion to gain possession of its <a href="https://investorplace.com/2024/06/treasure-hunt-3-small-cap-stocks-wall-street-hasnt-discovered-yet/">lung cancer treatment</a>. It also paid $800 million upfront to China&rsquo;s SystImmune for its signal-blocking therapy for cancer cells. It could be worth up to $8.4 billion.



AbbVie (NASDAQ:<a href="https://investorplace.com/stock-quotes/abbv-stock-quote/">ABBV</a>) also <a href="https://investorplace.com/2024/04/these-3-small-cap-stocks-are-up-304-in-2024-can-they-run-higher/">acquired ImmunoGen for $10 billion</a> and Johnson &amp; Johnson (NYSE:<a href="https://investorplace.com/stock-quotes/jnj-stock-quote/">JNJ</a>) bought Ambrx Biopharma for $2 billion. Previously, AstraZeneca (NYSE:<a href="https://investorplace.com/stock-quotes/azn-stock-quote/">AZN</a>), Gilead Sciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/gild-stock-quote/">GILD</a>) and Merck (NYSE:<a href="https://investorplace.com/stock-quotes/mrk-stock-quote/">MRK</a>) all made acquisitions in the cancer space to shore up their portfolios.



As patent expirations approach a critical stage for pharmaceutical stocks, Kazia Therapeutics could gain attention for Paxalisib.



<h2>Still a Risky Bet</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/08/doctor_medicine_dna_1600-300x169.jpg" alt="Various graphical representations of medical imagery are shown in front of a doctor using a tablet computer. DNA stock"><div>Source: Shutterstock / PopTika</div></div>Kazia Therapeutics stock has now traded in the 40-cent per share range for several days. Most of the gains were wrung out of the stock immediately after the results were published.



There could be a more massive upside in KZIA shares. Yet it still has the late-stage trials to go through, gaining permission from the FDA for fast-track approval and ultimately getting marketing approval.



Each step could excite the stock market again if the results are just as positive. Arguably staking a small claim to Kazia Therapeutics stock isn&rsquo;t a bad idea. I wouldn&rsquo;t go all-in because biotech investing is risky and full of unknowns. But for the speculative portion of your portfolio, buying a small tranche of the stock might not be a bad idea.



On the date of publication, Rich Duprey did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com <a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/">Publishing Guidelines</a>.



On the date of publication, the responsible editor did not have (either directly or indirectly) any positions in the securities mentioned in this article.
<div>Rich Duprey has written about stocks and investing for the past 20 years. His articles have appeared on Nasdaq.com, The Motley Fool, and Yahoo! Finance, and he has been referenced by U.S. and international publications, including MarketWatch, Financial Times, Forbes, Fast Company, USA Today, Milwaukee Journal Sentinel, Cheddar News, The Boston Globe, L&rsquo;Express, and numerous other news outlets.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>
The post <a href="https://investorplace.com/2024/07/kazia-therapeutics-stock-is-kzia-a-buyout-candidate-in-the-making/">Kazia Therapeutics Stock: Is KZIA a Buyout Candidate in the Making?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Kazia Therapeutics Stock: Is KZIA a Buyout Candidate in the Making?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
While investing in the best&nbsp;<a href="https://investorplace.com/stock-types/blue-chip-stocks/" target="_blank">blue chip stocks</a>&nbsp;to anchor your portfolio is always a good idea, I am always looking to diversify. A good way to do that is to invest in lesser-known but quality stocks under $10.



Lower-priced stocks have the advantage of being affordable so that you can buy more shares with less money. It&rsquo;s much cheaper to buy 100 shares of a $5 stock than to buy the same number of shares of an equity that cost $100 or more, right?



And these lower-priced stocks still can outperform the market. While the risks are higher, the rewards can be substantial, offering a tempting opportunity for investors willing to take on some level of risk.



I always suggest using the Portfolio Grader to help find the best stocks under $10. In fact, using a stock screening tool is essential in an exercise such as this.



Why? Because there are over&nbsp;<a href="https://money.usnews.com/investing/stocks/search?price-min=0&amp;price-max=10" target="_blank">2,100 stocks</a>&nbsp;on the market today are&nbsp;priced at $10 or less. No one can identify all of the best-performing stocks &ndash; or those that have the potential to perform &ndash; without using a screener like the Portfolio Grader to narrow the field.



The Portfolio Grader evaluates stocks based on various measurements, including earnings performance, growth, analyst sentiment, and momentum. The stocks under $10 on this list all score well enough to get at least a &ldquo;B&rdquo; rating in the Portfolio Grader tool.



<h2>Faraday Future Intelligent Electric (FFIE)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2023/07/ffie1600-1-300x169.png" alt="Person holding cellphone with logo of electric vehicle company Faraday Future Inc. (FFIE) on screen in front of business webpage. Focus on phone display. Unmodified photo."><div>Source: T. Schneider / Shutterstock.com</div></div>Faraday Future Intelligent Electric (NASDAQ:<a href="https://investorplace.com/stock-quotes/ffie-stock-quote/">FFIE</a>) designs, manufactures and sells electric vehicles and related products. The California company operates in the United States and China.



The company has gotten into some hot water with Nasdaq and its listing requirements because the stock is less than $1 &ndash; it has until Aug. 31 to get the stock price up &ndash; and for not always promptly filing financial reports. 



Those are red flags for sure, so already you know FFIE stock is a speculative play.



Although revenue in 2023 was only $800,000, it was the company&rsquo;s first year of revenue, as it&rsquo;s still very much a startup. Faraday delivered its first-ever vehicles in the third quarter of the year.



However, Faraday also has some interesting things in the works, as outlined in its <a href="https://investors.ff.com/news-releases/news-release-details/faraday-future-hosts-investor-community-day-and-highlights">July 20 Investor Day event</a>. Highlights included a look at the All-Ability aiHypercar, its user ecosystem, and the company&rsquo;s Auto Industry Bridge strategy.



The company raised the idea of launching a second, lower-priced automotive brand. &ldquo;A second brand could strike in the mass market with volume production, bringing everyone the &lsquo;AI car of the future&rsquo; and the &lsquo;AI car of the people&rsquo;. 



We are preparing to launch the Bridge and second brand strategies in a future event where we will share more details and our progress. We are hopeful to set sail together in the blue ocean market with potential partners,&rdquo;&nbsp;founder YT Jia said.



The company scheduled a July 31 shareholder vote that includes a proposal for a 1-for-40 reverse stock split to maintain its Nasdaq compliance. For now, FFIE stock gets a &ldquo;B&rdquo; rating in the Portfolio Grader.



<h2>SoundHound AI (SOUN)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/02/soun1600-1-300x169.png" alt="In this photo illustration, the SoundHound logo seen displayed on a smartphone. SOUN stock"><div>Source: rafapress / Shutterstock.com</div></div>SoundHound AI (NASDAQ:<a href="https://investorplace.com/stock-quotes/soun-stock-quote/">SOUN</a>) is an up-and-coming technology company that is using artificial intelligence and machine learning to create products that recognize and respond to verbal prompts.



SoundHound&rsquo;s platform is used by restaurants to <a href="https://investors.soundhound.com/news-releases/news-release-details/beef-o-bradys-rolls-out-soundhounds-advanced-voice-ai-ordering">automate food ordering</a>, reducing employee costs. Through its Dynamic Interaction platform, customers can verbally place complicated orders at a kiosk and pay without the intervention of an employee.



Another interesting use of SoundHound&rsquo;s platform is its employee training. Inexperienced workers can use SoundHound to ask questions about a process and SoundHound&rsquo;s AI will answer intelligently and walk the employee through the proper steps.



SoundHound also has a product that has a <a href="https://investors.soundhound.com/news-releases/news-release-details/soundhound-chat-ai-launches-peugeot-opel-and-vauxhall-vehicles">Chat AI product</a> &ndash; integrated with ChatGPT &ndash; that can manage navigation, advise about the weather or tell stories to bored children in the back seat.



I also like that SoundHound is shoring up its financial position. The company <a href="https://finance.yahoo.com/news/soundhound-ai-announces-early-debt-130000956.html">announced</a> that it reached an agreement with lenders to repay $100 million in outstanding debt. Once that&rsquo;s done, SoundHound will have zero debt and a cash balance of $180 million.



<a href="https://investors.soundhound.com/news-releases/news-release-details/soundhound-ai-reports-73-q1-revenue-growth-116-million-first">Revenue in the first quarter</a>&nbsp;was $11.6 million, up 73% from a year ago. And with a subscription and booking backlog of $682 million, up 80% from just a year ago, I think SoundHound will start turning a profit soon.



SOUN stock gets a &ldquo;B&rdquo; rating in the Portfolio Grader.



<h2>Kazia Therapeutics (KZIA)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/biotech1600-min-1-300x169.jpg" alt="an image of a microscope, NEXI stock"><div>Source: Shutterstock</div></div>Kazia Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/kzia-stock-quote/">KZIA</a>) is an Australian oncology company that&rsquo;s developing therapies for brain, liver and renal cancers.



The company&rsquo;s lead program is paxalisib, which is currently in Phase 3 trials as a treatment for glioblastoma, which is an aggressive form of brain cancer. Paxalisib is also in Phase 2 trials as a treatment for childhood brain cancers, brain metastases, and non-Hodgkin&rsquo;s lymphoma.



The stock had massive gains this month when it announced <a href="https://investorplace.com/2024/07/why-is-kazia-therapeutics-kzia-stock-up-300-today/">positive results</a> for paxalisib&rsquo;s glioblastoma trial. The company reported that patients who received paxalisib had a median overall survival period of 14.77 months, compared to 13.84 months for patients who did not receive the drug.



In a prespecified secondary analysis, the survival period for paxalisib patients was 15.54 months compared to 11.89 months for patients who did not take the drug.



Investing in biotech and pharma stocks can be very challenging because there&rsquo;s a lot of research &ndash; and a lot of expense &ndash; before a drug can even go to regulators for possible approval. But Kazia&rsquo;s work appears to be promising, and that&rsquo;s driving the momentum of KZIA stock right now.



Kazia stock is up 40% over the last month, and gets a &ldquo;B&rdquo; rating in the Portfolio Grader.



<h2>Koss (KOSS)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/07/koss1600-300x169.png" alt="Koss Porta Pro Wireless headphones on a round case like on your head on a white background with reflection"><div>Source: PhotOleh / Shutterstock.com</div></div>Koss (NASDAQ:<a href="https://investorplace.com/stock-quotes/koss-stock-quote/">KOSS</a>) is a manufacturer of headphones and accessories such as earbuds, electrostatic headphones and audio products for health care and education.



The company has been around for more than 60 years and came to renewed prominence in recent years as a popular meme stock. The meme factor makes Koss a volatile stock &ndash; shares jumped <a href="https://investorplace.com/2024/07/koss-stock-alert-koss-surges-90-on-renewed-meme-interest/">90% earlier this month</a> on speculative short-seller interest.



Earnings for the company&rsquo;s fiscal third quarter (ending March 31) showed weakening performance. Sales of $2.6 million was down from $3.3 million in the same quarter a year ago. Profits of $841,000 were down from $1.3 million on a year-over-year basis.



Koss is purely a meme stock play and should be treated with a lot of caution. If the stock jumps again &ndash; and odds are that it will &ndash; it would be wise to take profits at the peak.



KOSS stock is up 171% this year and gets a &ldquo;B&rdquo; rating in the Portfolio Grader.



<h2>VivoPower International (VVPR)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2023/05/electric-vehicle-ev-stocks-charging-black-neon-1600-300x169.jpg" alt="Electric car backlit by cyan blue neon light next to EV charger with cyan blue light and lightning bolt symbol, all against a black background. ev stocks to buy"><div>Source: shutterstock.com/JLStock</div></div>VivoPower International (NASDAQ:<a href="https://investorplace.com/stock-quotes/vvpr-stock-quote/">VVPR</a>) is an international battery technology and electric vehicle services company headquartered in the U.K. The company also operates in Australia, Canada, the Netherlands, the Philippines, the UAE and the U.S.



The company is preparing for a <a href="https://finance.yahoo.com/news/vivopower-announces-binding-heads-agreement-151900389.html">merger of its subsidiary</a>, Tembo E-LV, with Cactus Acquisition Corp. 1 Limited (NASDAQ:<a href="https://investorplace.com/stock-quotes/cctsw-stock-quote/">CCTSW</a>), a special purpose acquisition company in preparation for taking Tembo public. Tembo, which is an electric vehicle services company in the Netherlands. 



Following the merger, the new Tembo Group expects to be publicly traded on the Nasdaq exchange. The new company would have a valuation of $838 million, with VivoPower shareholders receiving 20% of the company.



Thus, VVPR stock is an interesting bet on EVs with heavy European exposure. VivoPower stock is up 37% this year and gets a &ldquo;B&rdquo; rating in the Portfolio Grader.



<h2>Soligenix (SNGX)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/07/sngx1600-300x169.png" alt="Soligenix is a leading biopharmaceutical firm developing drugs for rare diseases. It's renowned for solutions in oncology biodefense fields. SNGX stock"><div>Source: MacroEcon / Shutterstock.com</div></div>Soligenix (NASDAQ:<a href="https://investorplace.com/stock-quotes/sngx-stock-quote/">SNGX</a>) is a U.S. biopharmaceutical company that is working on a variety of products. It currently has several drug candidates in advanced stages of trials, including a treatment for early-stage cutaneous T-cell lymphoma in Phase 3 testing.



Soligenix has other Phase 2 tests underway for psoriasis, oral mucositis, and pediatric Crohn&rsquo;s disease.



But it&rsquo;s the early-stage cutaneous T-cell lymphoma trial that has investors excited. The stock jumped nearly 300% earlier this month &ndash; before giving some of those gains back &ndash; following a study testing HyBryte as a treatment). 



Six patients are enrolled in the yearlong study, with four of them completing at least 12 weeks of treatment. Of those, Soligenix says three patients already achieved treatment success, which is a 50% improvement in their cumulative mCAILS score compared to baseline. The fourth patient also saw improvement, the company said.



While this is a positive development, it&rsquo;s important to recognize that HyBryte is still a long way from making it to regulatory approval. But as a speculative play, SNGX stock has potential.



The stock is up 48% in the last month and has a &ldquo;B&rdquo; rating in the Portfolio Grader.



<h2>First Foundation (FFWM)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/05/piggy-bank-grad-300x169.jpg" alt="A pink piggy bank wearing a grad cap sits on a wooden table in front of a chalkboard."><div>Source: Shutterstock</div></div>First Foundation (NYSE:<a href="https://investorplace.com/stock-quotes/ffwm-stock-quote/">FFWM</a>) is a regional bank that&rsquo;s headquartered in Dallas, but has offices in California, Florida, Hawaii, Nevada and Texas.



The bank has $13.6 billion in assets as well as $10.1 billion of loans, deposits of $10.6 billion and stockholder equity of $929 million.



It also just completed an <a href="https://investor.ff-inc.com/news/news-details/2024/First-Foundation-Inc.-Closes-228-Million-Equity-Investment-Anchored-by-Fortress-Investment-Group-Canyon-Partners-Strategic-Value-Bank-Partners-and-North-Reef-Capital/default.aspx">investment deal</a> with several investment firms, including Fortress Investment Group, Canyon Partners, Strategic Value Bank Partners and North Reef Capital that injected $228 million into the company. First Foundation issued 11.3 million shares of stock valued at $4.10 each as part of the transaction.



The company is reporting second-quarter earnings on July 25, with <a href="https://investorplace.com/2024/07/why-is-first-foundation-ffwm-stock-down-27-today/">analysts expecting</a> flat adjusted earnings per share as well as revenue of $54.48 million. A year ago in the second quarter, FFWM saw $61.1 million in revenue and earnings of 7 cents per share.



Regional banking stocks have been challenging investments for the last few quarters, but FFWM appears to be on an upswing. The stock is up 25% in the last month and gets a &ldquo;B&rdquo; rating in the Portfolio Grader.



On the date of publication, neither Louis&nbsp;Navellier nor the InvestorPlace Research Staff member primarily responsible for this article held (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com <a href="https://url.us.m.mimecastprotect.com/s/AAadCPNlWWs3yKYns0yRM6?domain=investorplace.com/">Publishing Guidelines</a>.



On the date of publication, the responsible editor did not have (either directly or indirectly) and positions in the securities mentioned in this article.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>
The post <a href="https://investorplace.com/market360/2024/07/7-top-stocks-under-10-july-2024-edition/">7 Top Stocks Under $10: July 2024 Edition</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

7 Top Stocks Under $10: July 2024 Edition

Kazia Therapeutics files to sell $100M of American Depositary Shares

Kazia Therapeutics enters into licensing agreement with QIMR Berghofer

Kazia Therapeutics (KZIA) has released an update. Kazia Therapeutics has secured an exclusive worldwide license from QIMR Berghofer Medical Researc...

Kazia Therapeutics Advances Cancer Treatment Options

ABBV

ABVE

CCTSW

CURLF

DBGI

FCEL

FFIE

FFWM

FORD

GILD

JOBY

KOSS

MAXN

MCAC

NUWE

PLUG

SNGX

SNOA

SOUN

VVPR

Press Releases

Kazia announces presentation of new data at AACR Annual Meeting

Kazia Therapeutics licenses paxalisib to Sovargen for intractable seizures in rare central nervous system diseases

KAZIA REPORTS SUCCESSFUL STAGE 1 COMPLETION OF THE EVT801 PHASE 1 CLINICAL TRIAL IN ADVANCED CANCER PATIENTS

Kazia Granted 180-Day Extension by Nasdaq to Meet the Minimum Bid Price Requirement

Small Cap

KAZIA ANNOUNCES UPCOMING DIPG DATA PRESENTATIONS AT ISPNO AND PUBLICATION IN EUROPEAN JOURNAL OF CANCER

Kazia Therapeutics Announces Phase II/III Clinical Trial Results for Paxalisib in Glioblastoma

Biotech Experiences Strong Open Following Major Announcement

Citius Pharmaceuticals (CTXR) Nears Key FDA Decisions and Launch Plans for 2024

Citius Pharmaceuticals (CTXR) Eyes Breakthrough with Late-Stage Drug Pipeline Poised for Regulatory Approval

KAZIA EXECUTES LICENSING AGREEMENT WITH QIMR BERGHOFER

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Kazia Therapeutics

Kazia Therapeutics (KZIA) Forecast

Kazia Therapeutics (NASDAQ:KZIA) Stock, Quote.Headers.trade-ideas